EUVIMEDEUVIMED entdecken
Open Access

Prognostic stratification in DLBCL patients with aberrant MYC gene

Jian-Rong Li, Vikram R Shaw, Abi Parthasarathy, Yong Li, Christopher I Amos, Chao Cheng iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Jian-Rong Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-myc. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease characterized by a subset of patients who exhibit treatment resistance and poor prognoses. Genomic assays have been widely employed to identify high‐risk individuals characterized by rearrangements in the MYC , BCL2 and BCL6 genes. These patients typically undergo more aggressive therapeutic treatments; however, there remains a significant variation in their treatment outcomes. This study introduces an MYC signature score (MYCSS) derived from gene expression profiles, specifically designed to evaluate MYC overactivation in DLBCL patients. MYCSS was validated across several independent cohorts to assess its ability to stratify patients based on MYC ‐related genetic and molecular aberrations, enhancing the accuracy of prognostic evaluations compared to conventional MYC biomarkers. Our results indicate that MYCSS significantly refines prognostic accuracy beyond that of conventional MYC biomarkers focused on genetic aberrations. More importantly, we found that nearly 50% of patients identified as high risk by traditional MYC metrics actually share similar survival prospects with those having no MYC aberrations. These patients may benefit from standard GCB‐based therapies rather than more aggressive treatments. MYCSS provides a robust signature that identifies high‐risk patients, aiding in the precision treatment of DLBCL, and minimizing the potential for overtreatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-mycHumansPrognosisMaleFemaleMiddle AgedBiomarkers, TumorGenes, mycAgedAdultGene Expression Profiling

Stichwörter der Autor:innen

MYC rearrangementdiffuse large B‐cell lymphomagene signaturesprognostic stratification

Substanzen

Proto-Oncogene Proteins c-mycMYC protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
  • Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Chao Cheng

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • Center for Biomedical Informatics and Information Technology

Zitieren

APA

Li, J. R., Shaw, V. R., Parthasarathy, A., Li, Y., Amos, C. I., & Cheng, C. (2024). Prognostic stratification in DLBCL patients with aberrant MYC gene. British Journal of Haematology. https://doi.org/10.1111/bjh.19699

Vancouver

Li JR, Shaw VR, Parthasarathy A, Li Y, Amos CI, Cheng C. Prognostic stratification in DLBCL patients with aberrant MYC gene. British Journal of Haematology. 2024. doi:10.1111/bjh.19699

BibTeX
@article{Li2024,
  author = {Li, Jian-Rong and Shaw, Vikram R and Parthasarathy, Abi and Li, Yong and Amos, Christopher I and Cheng, Chao},
  title = {Prognostic stratification in DLBCL patients with aberrant MYC gene},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19699}
}
Kostenlos starten →